ReviewDermatology and therapy2025
Systematic Literature Reviews on the Disease Burden of Pediatric Psoriasis.
Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inequality and determinants of access to phototherapy among patients with psoriasis in Thailand.Skin health and disease · 2026Article
- Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases.Dermatology and therapy · 2026Review
- Effectiveness and Safety of IL-17A Inhibitors in Pediatric Psoriasis: A Real-World, Multicenter, International Study.Paediatric drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPediatric psoriasis is a chronic, inflammatory skin disease that substantially impacts the quality of life (QoL) of affected children and their families. Despite numerous literature reviews on psoriasis, data on pediatric populations remain sparse. We aimed to systematically identify and synthesize evidence on the epidemiological, humanistic, and economic burden of pediatric psoriasis, focusing on moderate-to-severe cases.
methodsWe conducted two systematic literature reviews (SLRs) of studies on pediatric psoriasis: one focusing on the epidemiological and disease burden of psoriasis of any severity, and one focusing on the humanistic and economic burden in moderate-to-severe psoriasis only. Data were collected from multiple databases, supplemented by additional sources.
resultsWe identified 56 studies across two SLRs, including interventional studies and observational real-world data from diverse geographic regions. The findings are consistent with the characterization of pediatric psoriasis as a multisystem disease, with higher burden in more severe cases. Prevalence appears to increase with age, and key risk factors are commonly associated with obesity and asthma. Comorbidities span mental health (depression, anxiety), metabolic (obesity, diabetes, hyperlipidemia), musculoskeletal (psoriatic arthritis), and gastrointestinal (celiac disease, ulcerative colitis, Crohn's disease) conditions. Disease severity correlates with higher rates of metabolic syndrome, poorer health-related QoL, and increased caregiver burden, including emotional distress and sleep disturbances. Economic data were limited, with no comprehensive cost-effectiveness analyses or utility measures identified.
conclusionsOur findings indicate limited evidence on the full spectrum of the pediatric psoriasis burden, particularly in moderate-to-severe psoriasis. Data are limited on the prevalence of moderate-to-severe cases, as well as healthcare resource utilization and economic impacts in this population, highlighting the need for further research to inform disease management and resource allocation. Emerging therapies may improve the lives of affected children and their caregivers, but further research is needed to fully capture their potential benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.